Nordic Life Science 1
TOP STORIES B U S I NES S D E AL LUNDBECK TO ACQU
IRE LONGBOARD The transaction is valued at approximately USD 2.6 billion in equity value and USD 2.5 billion net of cash, on a fully diluted basis. LONGBOARD PHARMACEUTICALS develops transformative medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction so far in preclinical and clinical studies. Bexicaserin is now being evaluated in a global phase III clinical program. “This transformative acquisition will become a cornerstone of Lundbeck’s neuro-rare franchise, with the potential to drive growth into the next decade. Bexicaserin addresses a critical unmet need for patients suffering from rare and severe epilepsies, for which there are very few good treatment options available. With this acquisition, we continue to execute on our Focused Innovator strategy, transforming the lives of patients suffering from severe brain disorders,” says Charl van Zyl, CEO, Lundbeck. NLS Charl van Zyl, CEO, Lundbeck